Request Demo

Last update 10 Jul 2026

Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

Last update 10 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Enzyme

Synonyms

CCH, Clostridial collagenase, Collagenase (Clostridium Histolyticum)

+ [14]

Target

Collagen

Action-

Mechanism

Collagenase replacements

Therapeutic Areas

NeoplasmsNervous System DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

CellulitePenile IndurationDupuytren Contracture+ [3]

Inactive Indication

BursitisCellulitisContusions+ [5]

Originator Organization

BioSpecifics Technologies Corp.

Active Organization

Pfizer Inc.

Auxilium Pharmaceuticals LLC

Asahi Kasei Pharma Corp.

+ [2]

Inactive Organization

Swedish Orphan Biovitrum ABEndo Pharmaceuticals, Inc.Advance Biofactures Corp.

+ [1]

License Organization

Asahi Kasei Pharma Corp.

Pfizer Inc.

Endo International Plc

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (02 Feb 2010),

Dupuytren Contracture

RegulationOrphan Drug (United States)

Structure/Sequence

Sequence Code 1049011

Source: *****

Sequence Code 1492779

Source: *****

Clinical Trials associated with Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

NCT06649539

/ RecruitingPhase 4IIT

Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men With Peyronie's Disease

Our team has previously demonstrated efficacy in performing a novel collagenase Clostridium histolyticum (CCH) injection protocol in men who previously failed to achieve a response to an initial 4 series of CCH.
The objective of the current study is to evaluate a protocol that incorporates limited in-office modeling for up to 4 series, followed by up to 2 additional salvage series to determine safety and efficacy compared to historical data.
Participants will receive up to 4 series of CCH injections using our previously published protocol, with mild in-office modeling. CCH injections are given on back-to back days, after which they are counseled to utilize Restorex and sildenafil daily, as instructed. Patients will undergo mild in-office modeling on day 2.
The sexual partners of study participants will also be invited to enroll in the study and will complete non-validated questionnaires detailing their level of support for the patient's treatment.

Start Date11 Oct 2024

Sponsor / Collaborator

Endo International Plc

NCT06065436

/ RecruitingNot ApplicableIIT

Impact of Concurrent Low Intensity Shockwave Therapy on Clinical Outcomes With Collagenase Clostridium Histolyticum in Peyronie's Disease: A Randomized Controlled Trial

The purpose of this research is to determine whether or not low-intensity shockwave therapy (LiSWT) with Xiaflex treatment will result in greater improvements to the curvature of the penis.

Start Date19 Jan 2024

Sponsor / Collaborator

Mayo Clinic

NCT06169319

/ CompletedPhase 2

A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)

This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.

Start Date03 Jan 2024

Sponsor / Collaborator-

100 Clinical Results associated with Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

100 Translational Medicine associated with Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

100 Patents (Medical) associated with Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

1,925

Literatures (Medical) associated with Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

01 Jul 2026·JOURNAL OF NEUROSCIENCE METHODS

A stereotactic injection method to establish a clinically relevant germinal matrix hemorrhage murine model

Article

Author: Tran, Celine Thao-Quyen ; Shahriari, Amirhossein ; Torres, Evelyn ; Ramos, Noah ; Jison, Gio ; Milo, Sydney ; Castañeyra-Ruiz, Leandro ; Padilla, Alejandra ; Latini, Alexandra ; Le, Michael ; Sabahat, Spencer ; Hanak, Brian W ; Lee, Seunghyun ; Muhonen, Michael ; Sato, Sora

BACKGROUND:

A germinal matrix hemorrhage (GMH) model that recapitulates both GMH-like tissue injury and intraventricular hemorrhage via injection of clostridial collagenase into the ganglionic eminence (GE; germinal matrix) has been well established in rats.

NEW METHOD:

A dose-response injection study was performed using weight-based collagenase doses extrapolated from established rat models. Reproducible targeting of the right GE in neonatal mice was achieved by the following stereotactic injection protocol: needle entry 1.1 mm lateral and 1.5 mm anterior to lambda, insertion to a depth of 1.3 mm prior to collagenase injection.

RESULTS:

High rates of ventriculomegaly were observed across collagenase injection groups compared with controls, with a significant dose-dependent effect. The weight-based equivalent dose of collagenase (0.024 collagenase digestion units [CDU] /μL) was identified as the optimal dose for this neonatal mouse model compared to lower or higher CDUs. Positive GFAP and CD68 labeling suggested accurate GE targeting. Intraventricular blood injection was used as a positive control.

COMPARISON WITH EXISTING METHODS:

A neonatal mouse model that recapitulates GMH-like tissue injury using stereotactic injection method and weight-based dosing extrapolated from prior reported rat models, while achieving high rates of hydrocephalus with minimal complications and mortality, has not yet been well established.

CONCLUSIONS:

Our group developed a GMH/posthemorrhagic hydrocephalus (PHH) mouse model with reproducible stereotactic injection coordinates. This model provides a foundation for future studies using genetically modified mouse strains aimed to advance understanding of the inflammation-related molecular mechanisms underlying acquired hydrocephalus and to support the preclinical evaluation of potential therapeutic interventions.

01 Jul 2026·ACTA ANAESTHESIOLOGICA SCANDINAVICA

Subcutaneous Tranexamic Acid Achieves Comparable Serum Concentrations to Intramuscular Administration During Haemorrhagic Shock in a Swine Model

Article

Author: Fuskevåg, Ole Martin ; Storm, Benjamin Stage ; Bakke, Håkon Kvåle ; Nielsen, Erik Waage ; Dietrichs, Erik Sveberg ; Lynghaug, Trine ; Nilsen, Bent Aksel

ABSTRACT:

Background:

Tranexamic acid is an antifibrinolytic agent reducing mortality when administered to trauma patients with haemorrhagic shock. This mortality reduction is time sensitive. Increased intramuscular dose administration has proven an effective alternative to intravenous administration in several studies and is used by some emergency medical services. However, subcutaneous administration has not been studied. Previous research indicates that subcutaneous tissue blood flow is more compromised during shock than muscle perfusion. Determining subcutaneous absorption is crucial to evaluate its potential as an alternative route and to assess the effect of accidental subcutaneous injection during intended intramuscular administration.

Methods:

In this experimental study using historical intramuscular and intravenous control groups, a total of six Norwegian Landrace pigs (40–50 kg) used in a trauma surgery course were subjected to various abdominal and thoracic traumas. After 1 h of surgery, the animals received tranexamic acid 30 mg/kg subcutaneously. Serum was sampled at 0, 5, 15, 25, 35, 45, 60, and 85 min after administration. Tranexamic acid serum concentration was measured using liquid chromatography–tandem mass spectrometry and compared to intramuscular and intravenous groups from previous studies, in which animals had received tranexamic acid 30 mg/kg intramuscular ( n = 7) or 15 mg/kg intravenous ( n = 8).

Results:

There was no statistical difference in serum concentrations between subcutaneous and intramuscular administration. Mean (±standard deviation) concentration after administration at 10, 45, and 85 min were 41.4 μg/mL (±19.0), 39.1 μg/mL (±8.9), and 33.4 μg/mL (±5.8), and for IM concentrations were 41.8 μg/mL (±18.9), 39.9 μg/mL (±7.8), and 44.2 μg/mL (±21.8). At 5 min, the concentration of both SC and IM administration was approximately half those observed after IV administration, but all concentrations were well above the 10–17 μg/mL concentration needed to inhibit fibrinolysis.

Conclusions:

Although subcutaneous blood flow is sensitive to shock, serum tranexamic acid concentrations after subcutaneous administration in shocked pigs were comparable to those achieved after intramuscular administration. Intramuscular administration should remain the preferred secondary route after the standard intravenous route, but inadvertent subcutaneous injection is likely to achieve therapeutic serum concentrations.

Editorial Comment:

This observational study in pigs undergoing hemorrhagic shock compared subcutaneous tranexamic acid administration to historical intravenous and intramuscular controls and found that plasma concentrations were comparable between routes. This suggests that inadvertent subcutaneous dosing during intramuscular injection likely achieves therapeutic levels. While promising, these results rely on historical controls and warrant further confirmatory studies. Intramuscular administration remains the preferred alternative to intravenous dosing for now.

01 Jun 2026·The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Efficacy and Safety of Tranexamic Acid in Pediatric Trauma: A Systematic Review and Meta-Analysis

Article

Author: Rath, Shree ; Tariq, Ammarah ; Alsabri, Mohammed ; Mahmoud, Yahya A. ; Aboali, Amira A. ; Abdul-Hafez, Hamza A. ; Khalifa, Mostafa A.

OBJECTIVE:

Tranexamic acid (TXA) is a widely used antifibrinolytic agent in surgical and trauma settings in adults. This study aimed to evaluate the efficacy and safety of TXA in pediatric trauma patients across various clinical outcomes.

METHODS:

A comprehensive literature search was conducted across 4 databases. We included clinical trials and observational studies that reported the use of TXA in pediatric trauma patients (aged ≤18 years). Data extraction and risk-of-bias assessment were performed by independent reviewers. Meta-analyses were conducted with RStudio software.

RESULTS:

A total of 12 studies (2 randomized controlled trials [RCTs] and 10 observational) involving 66,398 pediatric trauma patients were included. Tranexamic acid was not significantly associated with reduction in hospital mortality (OR = 1.06; 95% CI, 0.32–3.45) but was associated with significantly shorter hospital stays (mean difference [MD] = −1.49; 95% CI, −2.43 to −0.56). The need for emergency mechanical ventilation was higher among the TXA group (OR = 4.29; 95% CI, 2.52–7.31), whereas the need for mechanical ventilation at discharge was lower (OR = 0.23; 95% CI, 0.08–0.64). Tranexamic acid use did not significantly alter the risk of thromboembolic events (OR = 0.72; 95% CI, 0.19–2.79) or poor neurological outcomes (OR = 2.51; 95% CI, 0.86–7.35).

CONCLUSION:

Tranexamic acid may reduce hospital length of stay in pediatric trauma patients, with inconsistent effects on mortality and adverse events. Its use should be individualized based on injury severity and resource availability. Further high-quality research is needed to confirm these findings and clarify the role of TXA in pediatric trauma care.

News (Medical) associated with Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

10 Jul 2026

·www.prnewswire.com

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

July 8, 2026 -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic medical condition that causes nodules composed primarily of excess collagen to form in the connective tissue that supports the arch of the foot. The pivotal trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in pain versus placebo, as measured by the Average Daily Pain Intensity on the Numeric Rating Scale (NRS). It also met key ranked secondary endpoints related to difficulty and activity limitation as measured by the Foot Function Index (FFI) scale. The treatment benefit observed on the primary pain endpoint and key functional secondary endpoints was further supported by statistically significant improvements in additional secondary measures, including the FFI pain subscale, global assessments of improvement and disease severity, treatment satisfaction, and nodule characteristics. The safety profile of XIAFLEX in this study was consistent with the known safety profile of XIAFLEX from approved indications. Most adverse events were rated by the investigators as mild to moderate and there were no treatment-related serious adverse events. "We are excited to share the positive outcome for our Phase 3 clinical trial of plantar fibromatosis, a disease for which limited treatment options exist beyond symptom relief measures or surgery," said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova. "With these encouraging results, we intend to submit our application for this indication to the FDA in the fourth quarter of 2026 as part of an effort to expand our XIAFLEX portfolio and help address unmet patient needs." Based on claims data and projections, the company believes about 300,000 people will see a healthcare provider for their plantar fibromatosis in 2028, when Keenova expects to launch XIAFLEX for the indication. XIAFLEX is currently approved by the U.S. Food & Drug Administration for urological and orthopedic conditions. EN3835-309 was a double-blind, placebo-controlled Phase 3 trial to assess the overall reduction in the intensity of foot pain of XIAFLEX in the treatment of plantar fibromatosis. The pivotal trial enrolled 436 participants with plantar fibromatosis and at least one measurable, hard or firm, palpable fibrous nodule on clinical examination. Participants were randomly assigned to one of two treatment groups, with one group receiving XIAFLEX and the other receiving placebo. Each group received up to two treatments, with each treatment separated by a minimum of 28 days. Participants captured pain intensity on the Numeric Rating Scale (NRS) each day, and during several pre-determined follow-up visits, they completed additional questionnaires—including Subject Satisfaction With Treatment, Foot Function Index (FFI), Patient Global Impression of Severity (PGIS), and Patient Global Impression of Change (PGIC)—to report measures related to disability and activity limitation. Plantar fibromatosis, or Ledderhose disease, is a hyperproliferative fibrous tissue disorder resulting in the formation of collagen nodules along the plantar fascia, the thick connective tissue that supports the arch of the foot. The condition is chronic and progressive, leading to pain, walking impairment, and reductions in quality of life. There currently are no approved pharmacological treatments for plantar fibromatosis. Symptom management options include custom insoles (orthotics), topical treatments, over-the-counter pain and anti-inflammatory medications, radiation therapy, steroid injections, and, ultimately, surgery may be required to remove the nodules. Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives. Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations, and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug ApprovalRadiation Therapy

08 Jul 2026

·www.fiercepharma.com

Keenova gets on the good foot with Xiaflex trial win in rare tissue growth condition

After thriving in the market for more than a decade as the only treatment for Dupuytren's contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could set up the injectable biologic enzyme for approval in a third indication. The study of 436 patients with plantar fibromatosis achieved its primary endpoint, showing statistically significant and clinically meaningful reductions in pain versus placebo as measured by the Average Daily Pain Intensity on the Numeric Rating Scale (NRS). Patients received two injections, separated by a span of at least 28 days, and recorded foot pain intensity on a scale of 0-10, with a 2-point difference considered clinically meaningful. Keenova did not reveal figures related to the scoring. The study also aced its secondary endpoints as measured by the Foot Function Index (FFI) scale, a 23-item questionnaire which asks patients to rate their levels of pain, disability and activity limitation, also on a 0-10 basis. The safety profile of Xiaflex in the trial was consistent with its established indications. Most adverse events were rated by investigators as mild to moderate and there were no treatment-related serious adverse events, according to the company. Keenova chief scientific officer Marek Honczarenko, M.D., said that the company plans to submit for FDA approval in the fourth quarter of this year with hopes to launch Xiaflex in the indication in 2028. Plantar fibromatosis, which is also known as Ledderhose disease, causes lumps composed primarily of excess collagen to form in the connective tissue that supports the arch of the foot. It can cause pain, swelling, and difficulty walking. Based on claims data and projections, Keenova estimates that 300,000 people will see a healthcare provider for plantar fibromatosis in 2028. There is no medicine on the market specifically for plantar fibromatosis. Patients can get relief through radiation therapy or corticosteroid injections, with surgical interventions generally reserved as a last resort. Xiaflex works by breaking down collagen, allowing thickened cords in the hands (Dupuytren's contracture) and penis (Peyronie’s disease) to dissolve and soften. FDA approvals in those indications came in 2010 and 2013. Sales of Xiaflex have scaled up each year since it reached the market, coming to $546 million last year and $134 million in the first quarter of 2026, for an 11% year-over-year gain. Xiaflex was developed by Auxillium Pharmaceuticals, a Pennsylvania-based biotech which was bought out in 2014 by Endo for $2.6 billion. Last year, Ireland-based generics giants Endo and Mallinckrodt merged in a $6.7 billion deal. Eight months ago, the companies spun off their generics business as Par Health and rebranded as Keenova. In the first quarter of this year, Keenova reported revenue of $468 million, with $170 million coming from Acthar Gel, a treatment for an array of inflammatory and autoimmune conditions, which has seen a recent spike in sales thanks to a new self-injection delivery device.

Clinical ResultAcquisitionPhase 3Radiation Therapy

08 Jul 2026

·allsci.com

Keenova’s Phase III win positions Xiaflex for first FDA filing in plantar fibromatosis

Keenova Therapeutics has reported that collagenase clostridium histolyticum (Xiaflex) met its primary endpoint in a pivotal Phase III trial for plantar fibromatosis — a condition also known as Ledderhose disease — positioning the Ireland-based branded therapeutics company to file for a new FDA indication in Q4 2026. Plantar fibromatosis currently has no approved pharmacological treatment anywhere in the world, meaning a successful approval would create the first regulated drug option for a chronic, progressive condition that causes painful collagen nodules along the plantar fascia and can ultimately require surgery. The EN3835-309 PFI trial enrolled 436 participants with at least one measurable fibrous nodule and randomized them to receive up to two injections of collagenase clostridium histolyticum or placebo, separated by a minimum of 28 days. The primary endpoint — reduction in average daily pain intensity on the Numeric Rating Scale — was met with statistical significance and described as clinically meaningful. Key ranked secondary endpoints assessing difficulty and activity limitation on the Foot Function Index scale were also met, with additional statistically significant improvements reported across patient global assessments, treatment satisfaction, and nodule characteristics. No treatment-related serious adverse events occurred, and the safety profile was consistent with what has been established in Xiaflex’s approved indications. Competitive context The current standard of care consists entirely of off-label or procedural interventions — orthotics, steroid injections, radiation therapy, and fasciectomy — none of which carry regulatory sanction for this indication. Collagenase clostridium histolyticum is already FDA-approved for Dupuytren’s contracture (2010) and Peyronie’s disease (2013), both conditions involving pathological collagen accumulation, which provides a plausible mechanistic rationale and a well-characterized safety database. The enzyme degrades type I and type III collagen fibrils directly, disrupting the fibrous nodules that cause pain and functional limitation. Cross-trial comparisons with prior collagenase programs are limited by differences in anatomy, patient population, and endpoint selection, but the existing approval history meaningfully de-risks the regulatory path. Keenova’s commercial projection — approximately 300,000 patients seeking care for plantar fibromatosis annually by 2028, the anticipated launch year — suggests a market of meaningful scale for a specialty branded therapeutic. The company has not disclosed specific effect sizes, p-values, or nodule reduction data, which limits independent assessment of the magnitude of benefit. Full data presentation will be necessary before the clinical community can evaluate how the pain reduction observed compares to what patients currently achieve with existing symptom management approaches. The planned Q4 2026 FDA submission represents the next material milestone. If accepted for review, a standard 12-month review clock would align with the projected 2028 launch timeline. The result strengthens Keenova’s strategy of extending the Xiaflex franchise into additional collagen-driven conditions, building on the asset’s established regulatory and commercial infrastructure across rheumatology and urology. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 3Clinical ResultDrug ApprovalRadiation Therapy

100 Deals associated with Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	M09AB02	DB00048

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cellulite	United States	Endo Global Aesthetics Ltd.	06 Jul 2020
Penile Induration	European Union	Swedish Orphan Biovitrum AB	28 Feb 2011
Penile Induration	Iceland	Swedish Orphan Biovitrum AB	28 Feb 2011
Penile Induration	Liechtenstein	Swedish Orphan Biovitrum AB	28 Feb 2011
Penile Induration	Norway	Swedish Orphan Biovitrum AB	28 Feb 2011
Dupuytren Contracture	United States	Auxilium Pharmaceuticals LLC	02 Feb 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plantar Fibromatosis	Phase 3	United States	Endo Pharmaceuticals, Inc.	14 Feb 2022
Skin Diseases	Phase 3	United States	Endo Pharmaceuticals, Inc.	26 Apr 2018
Pain	Phase 3	Italy	Pfizer Inc.	27 Jan 2013
Fasciitis, Plantar	Phase 2	United States	-	03 Jan 2024
Contusions	Phase 2	United States	Endo Pharmaceuticals, Inc.	15 Jun 2022
Cutis Laxa	Phase 2	United States	Endo Pharmaceuticals, Inc.	01 Oct 2020
Cellulitis	Phase 2	United States	Endo Pharmaceuticals, Inc.	20 Dec 2019
Protoporphyria, Erythropoietic	Phase 2	United States	Endo Pharmaceuticals, Inc.	17 Nov 2017
Bursitis	Phase 2	Australia	Endo International Plc	04 Mar 2014
Lipoma	Phase 2	United States	Advance Biofactures Corp.	01 May 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05026216 (CTgov)	Phase 4	Cellulite	5	Qwo	nuelahxgos(vvbxykdzuk) = sitzzqizur kgwmarxswv (wsdnhrwyvc, 7.6) View more	-	28 May 2026
NCT05152173 (CTgov)	Phase 2	Plantar Fibromatosis	176	EN3835 (EN3835 Group)	ygftyrspom(spegrqvcqt) = fijnbuiwco aomaxfxfpl (sskkgwgrbt, 0.91) View more	-	27 Mar 2026
				Placebo (Placebo Group)	ygftyrspom(spegrqvcqt) = iibbfcwivc aomaxfxfpl (sskkgwgrbt, 0.89) View more
NCT02948842 (CTgov)	Phase 2	Urethral Stricture	5	Clostridium Histolyticum Collagenase+Saline	htmftgplog = ktpgpunlxo yrhukvtppq (csbkahtfew, hrzigtgjbt - kfpnqobyur) View more	-	03 Nov 2023
NCT04496167 (CTgov)	Phase 2	Periarthritis	198	EN3835 (EN3835)	juzmyzilqp(spwpfxzkzl) = popopeawbd mftuizvgea (evdfonmogs, 22.432) View more	-	13 Sep 2023
				Placebo (Placebo)	juzmyzilqp(spwpfxzkzl) = khkteplsrv mftuizvgea (evdfonmogs, 21.942) View more
NCT04677712 (MOBI, CTgov)	Phase 4	Contusions \| Cellulite \| Skin Diseases	48	CCH-aaes (Cohort 1: CCH-aaes)	ycdibrsczo = rmivxyvdvu rdctojjmve (cmfndpkpjy, luageqrnjq - lpmovuhcvv) View more	-	21 Aug 2023
				Compression (Cohort 2: CCH-aaes + Compression Garment)	ycdibrsczo = zwxsfigvyw rdctojjmve (cmfndpkpjy, jojmqdwjyk - xqsmgusmcy) View more
NCT04786106 (AUA2023)	Phase 4	Cardiovascular Diseases	40	Collagenase Clostridium Histolyticum + traction + sildenafil	xzokjxoreg(eekvsmspep) = gpvoavmpwy dxdmwcsguq (fxkhmsrpic ) View more	-	01 Apr 2023
				Collagenase Clostridium Histolyticum (Penile surgery + traction + sildenafil)	xzokjxoreg(eekvsmspep) = zipcsixllq dxdmwcsguq (fxkhmsrpic ) View more
NCT04580303 (CTgov)	Phase 2	Cellulite \| Cutis Laxa	35	CCH (Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttocks))	bqlcgveicn = focatdkkcl ztfltacinv (qynqixsnkw, fnukavbouy - bmphzzuzrs) View more	-	28 Sep 2022
				CCH (Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks))	bqlcgveicn = pjcmsmxldx ztfltacinv (qynqixsnkw, rdtinlnxye - thctxwfzrw) View more
NCT04496167 (Corporate Publications) Manual	Phase 2	Bursitis	198	Collagenase Clostridium Histolyticum	aecartzvaq(wcnlwwmozl) = While Phase 2 study participants receiving up to three doses of CCH showed some improvement in the change from baseline in the adapted American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Form composite score for the affected shoulder at the Day 95 visit, the difference compared to those study participants receiving placebo was not statistically significant. kbxldtokuw (qjsntljnyi ) View more	Negative	01 Jul 2022
				Placebo
AUA2022	Phase 3	Penile Induration	832	Collagenase clostridium histolyticum (CCH)	cpiriqoiko(lilgbgvktx) = lgcgqdrisj asxpndpbsk (jvpwaaczmv )	-	01 May 2022
				Placebo	cpiriqoiko(lilgbgvktx) = aydurxjkod asxpndpbsk (jvpwaaczmv )
NCT04786106 (AUA2022)	Phase 4	Cardiovascular Diseases	40	Collagenase Clostridium Histolyticum + traction + sildenafil	xsptqpicxy(wdxurbobhv) = lvnxwqyguc qpqtznoexo (iwtpuuftqt ) View more	-	01 May 2022
				Collagenase Clostridium Histolyticum (Penile surgery + traction + sildenafil)	xsptqpicxy(wdxurbobhv) = awowscbrzq qpqtznoexo (iwtpuuftqt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis